肿瘤药学2019，Vol.9Issue(2)：212-218,7.DOI:10.3969/j.issn.2095-1264.2019.02.08
二甲双胍联合索拉非尼对HepG2干细胞样细胞增殖的影响
Effects of Metformin Combined with Sorafenib on the Proliferation of HepG2 Stem Cell-Like Cells
XUAN Yang 1WANG Ruichen1
作者信息
- 1. Department of Pharmacy, Jiangsu Cancer Hospital / Jiangsu Institute of Cancer Research / The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210009, China
- 折叠
摘要
Abstract
Objective To investigate the effects of metformin combined with sorafenib on the proliferation of HepG2 stem cell-like cells. Methods Human hepatocellular carcinoma cell line HepG2 was enriched in serum-free stem cell enrichment medium to obtain stem cell-like cell suspension spheres. The morphological changes during the growth of suspension spheres were observed and recorded. The diameter of suspension spheres was measured and the number of suspension spheres was calculated. HepG2 stem cell-like cells and HepG2 cells were inoculated in soft agar gel to compare the cloning ability in the two groups. In order to select the best time for drug action, HepG2 stem cell-like cells and HepG2 cells were treated with different concentrations of sorafenib for 24h, 48h or 72h, respectively. HepG2 stem cell-like cells were treated with 1, 3, 5 mM metformin combined with 5 uM sorafenib, respectively. Then the proliferation activity of HepG2 stem cell-like cells was detected by CCK8 assay. The growth inhibition rate and suspension ball diameter of HepG2 stem cell-like cells were compared between the combination group and sorafenib group. Results The optimum time was 48 hours for metformin combined with sorafenib to treat HepG2 stem cell-like cells. There were significant differences in cell growth inhibition rate and suspension sphere diameter between different concentrations of combined drugs and 5 uM sorafenib alone for 48 hours (P< 0.05). The inhibition rate of cell proliferation was higher in the combined treatment group of 3 mM and 5 mM for 48 hours (P<0.05), and the cell suspension ball diameter was smaller (P< 0.05). Conclusion Metformin combined with sorafenib can inhibit the proliferation of HepG2 stem cell-like cells and en- hance their sensitivity to sorafenib, which provides a scientific basis for clinical treatment of hepatocellular carcinoma with metformin com-bined with sorafenib.关键词
二甲双胍/索拉非尼/联合用药/干细胞/增殖Key words
Metformin/Sorafenib/Combined medication/Stem cell-like cells/Proliferation分类
医药卫生引用本文复制引用
XUAN Yang,WANG Ruichen..二甲双胍联合索拉非尼对HepG2干细胞样细胞增殖的影响[J].肿瘤药学,2019,9(2):212-218,7.
